申请人:TAIHO PHARMACEUTICAL CO LTD
公开号:WO2021215544A1
公开(公告)日:2021-10-28
Compounds and pharmaceutically acceptable salts thereof inhibit the G12D mutant of KRAS protein and are expected to have utility as therapeutic agents, for example, for the treatment of cancer.
化合物及其药用可接受的盐抑制KRAS蛋白的G12D突变体,预计可作为治疗剂的用途,例如用于癌症的治疗。